Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa
Open Access
- 20 August 2008
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 28 (6) , 663-673
Abstract
Summary: Background Many oral 5‐aminosalicylic acid (5‐ASA) formulations are designed to maximize 5‐ASA release in the colon where it acts topically on the colonic mucosa. Delayed‐release formulations and azo‐prodrugs minimize 5‐ASA absorption in the upper gastrointestinal (GI) tract.Aims To review methods for assessing 5‐ASA release and colonic distribution from oral formulations, and the potential use of this information for guiding clinical decisions.Methods PubMed and recent conference abstracts were searched for articles describing techniques used to assess 5‐ASA release from ulcerative colitis (UC) therapies.Results In‐vitro GI models, although unable to simulate more complex aspects of GI physiology, can provide useful data on 5‐ASA release kinetics and bioaccessibility. Gamma‐scintigraphy is useful for investigating GI disintegration of different formulations, but may not accurately reflect 5‐ASA distribution. Plasma pharmacokinetic studies provide data on systemic exposure, but not on colonic distribution or mucosal uptake. Mucosal biopsies provide direct evidence of colonic distribution and may predict clinical efficacy, but must be interpreted cautiously because of considerable inter‐subject variability and other confounding factors.Conclusion While assessment of 5‐ASA release is important, limitations of individual measurement techniques mean that randomized clinical studies in UC patients remain the best guide for dosing and treatment regimen decisions.Keywords
This publication has 78 references indexed in Scilit:
- Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitisAlimentary Pharmacology & Therapeutics, 2007
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2004
- Clinical Pharmacokinetics of Slow Release MesalazineClinical Pharmacokinetics, 2000
- Regular review: Ulcerative colitisBMJ, 2000
- Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteersAlimentary Pharmacology & Therapeutics, 1994
- Localization of Drug Release Sites from an Oral Sustained‐Release Formulation of 5‐ASA (Pentasa®) in the Gastrointestinal Tract Using Gamma ScintigraphyThe Journal of Clinical Pharmacology, 1993
- Dissolution profiles of mesalazine formulationsin vitroInternational Journal of Clinical Pharmacy, 1990
- Gastrointestinal Behavior of Orally Administered Radiolabeled Erythromycin Pellets in Man as Determined by Gamma ScintigraphyThe Journal of Clinical Pharmacology, 1990
- Mesalazine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Chronic Inflammatory Bowel DiseaseDrugs, 1989
- Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic AcidClinical Pharmacokinetics, 1985